InflaRx (IFRX) Other Non-Current Assets (2016 - 2026)
InflaRx's (IFRX) quarterly Other Non-Current Assets came in at $162958.4 in Q1 2026, down 18.88% year-on-year from $200882.6 in Q1 2025, and down 7.41% quarter-over-quarter from $176001.1 in Q4 2025.
InflaRx (IFRX) Other Non-Current Assets (2016 - 2026) Analysis & Trends
InflaRx has disclosed Other Non-Current Assets across 11 years of filings, most recently posting $162958.4 for Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $162958.4, down 18.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $162958.4 (down 18.88% YoY), and the FY2025 annual result was $176001.1, down 96.42% from the prior year.
- Other Non-Current Assets came in at $162958.4 for Q1 2026 at InflaRx, down from $176001.1 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $8.1 million in Q1 2023 to a low of -$3.4 million in Q4 2022.
- The 5-year median for Other Non-Current Assets is $276803.8 (2023), against an average of $1.8 million.
- Peak annual rise in Other Non-Current Assets reached 1675.82% in 2024, while the deepest fall reached 101.7% in 2024.
- InflaRx's Other Non-Current Assets stood at -$3.4 million in 2022, then soared by 108.2% to $276803.8 in 2023, then surged by 1675.82% to $4.9 million in 2024, then tumbled by 96.42% to $176001.1 in 2025, then declined by 7.41% to $162958.4 in 2026.
- The last three Other Non-Current Assets figures came in at $162958.4 (Q1 2026), $176001.1 (Q4 2025), and $192259.3 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | 162,958.43 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162,958.43 |
| Dec 31, 2025 | 176,001.05 |
| Sep 30, 2025 | 192,259.29 |
| Jun 30, 2025 | 201,167.35 |
| Mar 31, 2025 | 200,882.58 |
| Dec 31, 2024 | 4.92 Mn |
| Sep 30, 2024 | 4.08 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Mar 31, 2024 | -137,475.82 |
| Dec 31, 2023 | 276,803.83 |
| Sep 30, 2023 | 4.86 Mn |
| Jun 30, 2023 | 6.86 Mn |
| Mar 31, 2023 | 8.07 Mn |
| Dec 31, 2022 | -3.38 Mn |
| Sep 30, 2022 | 3.11 Mn |
| Jun 30, 2022 | 652,871.17 |
| Mar 31, 2022 | -1.58 Mn |
| Dec 31, 2021 | -8.12 Mn |
| Sep 30, 2021 | -1.37 Mn |
| Jun 30, 2021 | 207,135.89 |